|Bid||160.52 x 100|
|Ask||171.23 x 200|
|Day's Range||167.27 - 172.18|
|52 Week Range||83.27 - 179.76|
|PE Ratio (TTM)||62.91|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.
The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.